Literature DB >> 12150334

Clinical characteristics and genetic screening of an extended family with MEN2A.

E Algün1, N Abaci, M Kösem, C Kotan, B Köseoğlu, H Boztepe, R Sekeroğlu, H Aslan, C Topal, H Ayakta, I Uygan, F Alagöl, N Erginel-Unaltuna, H Aksoy.   

Abstract

MEN-2A is characterized by medullary thyroid carcinoma (MTC) with pheochromocytoma and sometimes parathyroid adenoma. In affected members of the family, the risk of MTC is about 100%. Biochemical screening allows tumors to be detected early but even at this stage treatment is not always curative. Missense mutations in exon 10 and 11 of the RET proto-oncogene are associated with MEN-2A. Early detection of this mutation by DNA analysis allows the identification of the carriers of the gene. We performed genetic screening in 88 members of an extended family with MEN-2A and found 18 members positive for RET mutation (Cys634Gly). Only three of these 18 RET positive cases had a previous diagnosis of medullary cancer and/or pheochromocytoma. Up to now, 12 of the RET positive cases have undergone thyroidectomy. There was extended disease with cervical lymph node metastasis in 6 of them, bilateral medullary microcancer in 3 and c-cell hyperplasia in the remaining 3. Three of the 18 RET positive patients had also pheochromocytoma. Primary hyperparathyroidism was present in only one patient. The mean age of diagnosis of medullary cancer was between 25-50 yr and mean age of death was between 35-95 yr in affected members of the family. The family had many other affected members in other cities in Turkey and in other countries throughout the world from Australia to the Netherlands. So this family is perhaps one of the most extended families with MEN-2A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150334     DOI: 10.1007/BF03345083

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Results of a screening program for multiple endocrine neoplasia type 2A: a clinical study of a Japanese family.

Authors:  T Shimotake; N Iwai; J Yanagihara; T Kobayashi; S Takai
Journal:  Henry Ford Hosp Med J       Date:  1989

2.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

Review 3.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

4.  False-positive results of basal and pentagastrin-stimulated calcitonin in non-gene carriers of multiple endocrine neoplasia type 2A.

Authors:  G Hernández; R Simó; J Oriola; J Mesa
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

Review 5.  Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma.

Authors:  T C Lairmore; M M Frisella; S A Wells
Journal:  Ann Med       Date:  1996-10       Impact factor: 4.709

6.  C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases.

Authors:  S Guyetant; N Wion-Barbot; M C Rousselet; B Franc; J C Bigorgne; J P Saint-Andre
Journal:  Hum Pathol       Date:  1994-05       Impact factor: 3.466

7.  Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage.

Authors:  N E Simpson; K K Kidd; P J Goodfellow; H McDermid; S Myers; J R Kidd; C E Jackson; A M Duncan; L A Farrer; K Brasch
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.

Authors:  E Chiefari; D Russo; D Giuffrida; G A Zampa; D Meringolo; F Arturi; I Chiodini; D Bianchi; M Attard; V Trischitta; R Bruno; P Giannasio; A Pontecorvi; S Filetti
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

9.  Identification of the Cys634-->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis.

Authors:  I Ceccherini; C Romei; V Barone; F Pacini; E Martino; A Loviselli; A Pinchera; G Romeo
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

10.  Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Authors:  C Romei; R Elisei; A Pinchera; I Ceccherini; E Molinaro; F Mancusi; E Martino; G Romeo; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.